Examkin

Question

Difficulty: HardPharmacologic Interventions

A 72-year-old man is brought to the outpatient neurology clinic by his wife due to new-onset visual hallucinations. For the past three weeks, he has been seeing 'small children playing in the living room' who do not interact with him. The patient retains insight that these visions are not real, but they are becoming increasingly distressing. He has a 6-year history of Parkinson disease, and his motor symptoms have been reasonably well controlled. Vital signs are within normal limits. Physical examination reveals a resting tremor in the right hand, bilateral bradykinesia, and cogwheel rigidity, all of which are stable compared to his previous visit. Montreal Cognitive Assessment score is 26/30. Laboratory studies, including a complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone, and vitamin B12 levels, are within normal limits. Urinalysis is unremarkable. His current medication regimen includes carbidopa-levodopa, ropinirole, selegiline, and benztropine.

Arrange the following pharmacologic interventions in the most appropriate sequential order for managing this patient's psychotic symptoms, from the immediate first step to the final step if symptoms persist.

  1. 1Discontinue oral benztropine
  2. 2Discontinue oral selegiline
  3. 3Discontinue oral ropinirole
  4. 4Initiate oral quetiapine

Answer

The correct sequence for managing Parkinson disease psychosis is to first discontinue anticholinergics (benztropine), followed by MAO-B inhibitors (selegiline), then dopamine agonists (ropinirole), and finally, if symptoms persist, initiate an atypical antipsychotic (quetiapine).
The correct sequence adheres to the Movement Disorder Society guidelines for managing Parkinson disease psychosis. The fundamental principle is to sequentially discontinue non-essential, high-risk medications before adding new psychiatric drugs. The order of discontinuation strictly follows the rule of stopping drugs with the highest risk of cognitive side effects and lowest motor efficacy first. Anticholinergics (benztropine) are stopped immediately. Next, amantadine and MAO-B inhibitors (selegiline) are withdrawn. If hallucinations persist, dopamine agonists (ropinirole) are tapered and stopped. Only if these measures fail, or if severe motor symptoms preclude reducing the primary carbidopa-levodopa dose, is an atypical antipsychotic with low D2 affinity (such as quetiapine, clozapine, or the 5-HT2A inverse agonist pimavanserin) initiated.

Step-by-Step Solution

1
Rule out secondary causes of psychosis and delirium.
Urinalysis, metabolic panels, and lack of acute cognitive decline (MoCA 26/30) suggest the hallucinations are a primary complication of Parkinson disease medications rather than an acute systemic illness.
Infections, metabolic derangements, and polypharmacy are common triggers for acute mental status changes in the elderly and must be excluded first.
2
Identify the first medication to discontinue based on the risk-to-benefit ratio.
Discontinue oral benztropine.
The standard protocol for Parkinson disease psychosis requires sequential tapering of adjunctive medications. Anticholinergics are stopped first because they cause significant neuropsychiatric side effects and offer minimal benefit for core parkinsonian symptoms.
3
Identify the second medication to discontinue if symptoms persist.
Discontinue oral selegiline.
Amantadine and MAO-B inhibitors are the next to be removed, as they increase dopaminergic tone and carry hallucination risks without matching the efficacy of carbidopa-levodopa.
4
Identify the third medication to discontinue if symptoms persist.
Discontinue oral ropinirole.
Dopamine agonists strongly contribute to psychosis and impulse control disorders. They must be tapered off before considering reductions to the patient's primary carbidopa-levodopa regimen.
5
Determine the final pharmacologic step for refractory symptoms.
Initiate oral quetiapine.
If psychosis persists despite discontinuing all adjunctive medications (and the patient cannot tolerate carbidopa-levodopa reduction due to worsening motor symptoms), adding a targeted atypical antipsychotic like quetiapine, clozapine, or pimavanserin is indicated.

Key Concept

Pharmacologic management of Parkinson disease psychosis follows a strict stepwise reduction of adjunctive medications (Anticholinergics →\rightarrow Amantadine →\rightarrow MAO-B inhibitors →\rightarrow Dopamine agonists →\rightarrow COMT inhibitors) before adding specialized atypical antipsychotics (quetiapine, clozapine, or pimavanserin) to avoid worsening motor symptoms.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic